Catalyst Brief

← Calendar

Readoutin 14d

Innovent Biologics (Suzhou) Co. Ltd. — Irinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI)

Phase 3 primary completion: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001).

Date
Dec 2026
Type
Readout
Indication
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Innovent Biologics (Suzhou) Co. Ltd.

  1. Dec2026